Abstract:Thalassemia encompasses a group of inherited hemoglobin disorders characterized by reduced or absent production of the α- or β-globin chains, leading to anemia and other complications. Current management relies on lifelong blood transfusions and iron chelation, which is burdensome for patients. This review summarizes the emerging therapeutic potential of modulating microRNAs (miRNAs) to treat thalassemia. MiRNAs are small non-coding RNAs that regulate gene expression through sequence-specific binding to messenger RNAs (mRNAs). While they commonly repress gene expression by binding to the 3' untranslated regions (UTRs) of target mRNAs, miRNAs can also interact with 5'UTRs and gene promoters to activate gene expression. Many miRNAs are now recognized as critical regulators of erythropoiesis and are abnormally expressed in β-thalassemia. Therapeutically restoring levels of deficient miRNAs or inhibiting overexpression through miRNA mimics or inhibitors (antagomir), respectively, has shown preclinical efficacy in ameliorating thalassemic phenotypes. The miR-144/451 cluster is especially compelling for targeted upregulation to reactivate fetal hemoglobin synthesis. Advances in delivery systems are addressing previous challenges in stability and targeting of miRNA-based drugs. While still early, gene therapy studies suggest combinatorial approaches with miRNA modulation may provide synergistic benefits. Several key considerations remain including enhancing delivery, minimizing off-target effects, and demonstrating long-term safety and efficacy. While no miRNA therapies have yet progressed to clinical testing for thalassemia specifically, important lessons are being learned through clinical trials for other diseases and conditions, such as cancer, cardiovascular diseases, and viral. If limitations can be overcome through multi-disciplinary collaboration, miRNAs hold great promise to expand and transform treatment options for thalassemia in the future by precisely targeting pathogenic molecular networks. Ongoing innovations, such as advancements in miRNA delivery systems, improved targeting mechanisms, and enhanced understanding of miRNA biology, continue to drive progress in this emerging field towards realizing the clinical potential of miRNA-based medicines for thalassemia patients.

RNA therapeutics for β-thalassemia

RNA therapeutics for the treatment of blood disorders

RNA therapeutics for treatment of diabetes

RNA therapeutics for metabolic disorders

Potential Use of MicroRNA Technology in Thalassemia Therapy

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

RNA therapeutics in cancer treatment

β-Thalassemia gene editing therapy: Advancements and difficulties

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

Progress of CRISPR-Cas9 in Treatment of β-thalassemia

Recent applications of RNA therapeutic in clinics

Molecular genetics of β-thalassemia: A narrative review

[Overview of new approaches to β-thalassemia treatment]

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

RNA therapeutics for disorders of excretory system

RNA therapeutics: Molecular mechanisms, and potential clinical translations

RNA-based Therapeutics: an Overview and Prospectus

CRISPR/Cas9 in the treatment of -thalassemia

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

Current Advances in RNA Therapeutics for Human Diseases

Repair of Thalassemic Human Β-Globin Mrna in Cultured Erythroid Cells by Antisense RNA